U.S., July 28 -- ClinicalTrials.gov registry received information related to the study (NCT07726992) titled 'A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC' on July 21.

Brief Summary: This is a multicenter, randomized, Double-blind phase III study to determine the efficacy and safety of intravesical SHR-1501 combined with Bacillus Calmette Guerin (BCG) versus Placebo Combined with BCG in patients with high-risk BCG-naive Papillary-Only non-muscle-invasive bladder cancer (NMIBC)

Study Start Date: July, 2026

Study Type: INTERVENTIONAL

Condition: Papillary-Only Non-muscle-invasive Bladder Cancer

Intervention: DRUG: SHR-1501+BCG

SHR-1501+BCG

DRUG: Placebo +BCG

Placebo +B...